lilly retatrutide trial Eli just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Eli Lilly stock jumps on

If you microdose retatrutide and lose the glucagon component, you might go from 24% weight loss to 15% weight loss, essentially converting your triple agonist into a less efficient version of what you could get from semaglutide alone

[DOI] [PubMed] [Google Scholar] 53.Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Compared to popular GLP-1RAs like semaglutide, orforglipron does not require injection or an absorption enhancer with fasting to achieve exposure, and it can be taken without water or food restrictions, according to Phase 1 pharmacokinetic data

Dehydration can also lead to electrolyte imbalance, another possible source of headaches, so consider tackling two potential issues at once with electrolyte-rich drinks, like Virtas low-carb homemade electrolyte drink recipe

One AssuredPartners case study found GLP1 users saved about $560 per person per year in medical costs but against an average annual drug cost of $6,540, the nearterm ROI is negative for most employers

It is the first of these medications to interact with two hormones in the body, which is why researchers believe it manages blood sugar levels better than previous medicines and helps people lose more weight